Poxel S.A. announced that the Poxel team will participate at several upcoming scientific conferences related to X-linked adrenoleukodystrophy (ALD), a severe orphan neurometabolic disease with no approved therapies. Poxel's scientific team will present data and plans pertaining to ALD that align with the recently announced new strategic direction of increasing Poxel's focus on rare metabolic diseases. Phase 2a clinical Proof of Concept (POC) biomarker studies, examining PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN), the most common subtype of ALD which affects the nervous system and adrenal glands, are planned to initiate in early 2022 with data readouts anticipated by year end 2022.

Poxel is committed to focus its pipeline on high value, rare metabolic indications and NASH, with the goal of creating pipeline synergies, maximizing resources, and driving shareholder value.